Mobile

Program to Give the Drug Aztreonam Lysine for Inhalation to Patients with Cystic Fibrosis and infection by the Bacteria Pseudomonas aeruginosa Who Have Limited Treatment Options and are at Risk for Di...

Mise à jour : Il y a 5 ans
Référence : EUCTR2015-000396-26

Program to Give the Drug Aztreonam Lysine for Inhalation to Patients with Cystic Fibrosis and infection by the Bacteria Pseudomonas aeruginosa Who Have Limited Treatment Options and are at Risk for Disease Progression

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective of this program is to provide expanded access to aztreonam lysine for inhalation 75 mng prior to its commercial availability to patients with cystic fibrosis and chronic P. aeruginosa airway infection who have limited treatment options and are at risk for disease progression.

Critère d'inclusion

  • Adult and paediatric cystic fibrosis (CF) patients with pulmonary Pseudomonas aeruginosa (PA) infection

Liens